Global EditionASIA 中文双语Français
Home / China / HK Macao

Hong Kong researchers discover new antiviral strategy to treat COVID-19

Xinhua | Updated: 2020-10-12 19:57
Share - WeChat

HONG KONG -- The University of Hong Kong on Monday announced that a class of metallodrugs currently used in the treatment of other infectious diseases can potently suppress the SARS-CoV-2 virus that causes COVID-19.

According to researchers from the university, ranitidine bismuth citrate (RBC), a commonly used anti-ulcer drug which contains the metal Bismuth, has been demonstrated to greatly reduce viral loads by over 1,000-folds in SARS-CoV-2-infected cells.

In a golden Syrian hamster model, RBC suppressed SARS-CoV-2 replications to reduce viral loads by over 100 folds in both the upper and lower respiratory tracts, and mitigated virus-associated pneumonia.

In treating severe COVID-19 cases of infected hamsters, when compared to the group treated by Remdesivir, a broad-spectrum antiviral drug that has been reported to show efficacy towards SARS-CoV-2, and the control group, the animals treated by RBC showed remarkably lower level of prognostic markers and other major pro-inflammatory cytokines and chemokines.

Furthermore, RBC exhibited a low cytotoxicity with a high selectivity index at 975 as compared to Remdesivir which has a low selectivity index at 129. Concerning the cytotoxicity assessment, the larger the selectivity index number is, the safer the drug is.

The researchers said the findings provide a new and readily available therapeutic option with high clinical potential for COVID-19 infections.

The study has been published in the online scientific journal Nature Microbiology. A related patent has been filed in the United States.

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349